Cargando…
Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771262/ https://www.ncbi.nlm.nih.gov/pubmed/36535013 http://dx.doi.org/10.1097/CM9.0000000000002121 |
| _version_ | 1784854784925237248 |
|---|---|
| author | Tian, Shen Li, Hao Li, Renhua Ran, Liang Li, Shu Wu, Juan Xu, Zhou Liang, Xinyu Chen, Yuling Xiao, Jun Wei, Jiaying Ma, Chenyu Song, Jingyu She, Ruiling Wu, Kainan Kong, Lingquan |
| author_facet | Tian, Shen Li, Hao Li, Renhua Ran, Liang Li, Shu Wu, Juan Xu, Zhou Liang, Xinyu Chen, Yuling Xiao, Jun Wei, Jiaying Ma, Chenyu Song, Jingyu She, Ruiling Wu, Kainan Kong, Lingquan |
| author_sort | Tian, Shen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9771262 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97712622022-12-22 Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors Tian, Shen Li, Hao Li, Renhua Ran, Liang Li, Shu Wu, Juan Xu, Zhou Liang, Xinyu Chen, Yuling Xiao, Jun Wei, Jiaying Ma, Chenyu Song, Jingyu She, Ruiling Wu, Kainan Kong, Lingquan Chin Med J (Engl) Correspondence Lippincott Williams & Wilkins 2022-10-05 2022-11-30 /pmc/articles/PMC9771262/ /pubmed/36535013 http://dx.doi.org/10.1097/CM9.0000000000002121 Text en Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
| spellingShingle | Correspondence Tian, Shen Li, Hao Li, Renhua Ran, Liang Li, Shu Wu, Juan Xu, Zhou Liang, Xinyu Chen, Yuling Xiao, Jun Wei, Jiaying Ma, Chenyu Song, Jingyu She, Ruiling Wu, Kainan Kong, Lingquan Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors |
| title | Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors |
| title_full | Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors |
| title_fullStr | Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors |
| title_full_unstemmed | Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors |
| title_short | Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors |
| title_sort | prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771262/ https://www.ncbi.nlm.nih.gov/pubmed/36535013 http://dx.doi.org/10.1097/CM9.0000000000002121 |
| work_keys_str_mv | AT tianshen prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT lihao prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT lirenhua prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT ranliang prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT lishu prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT wujuan prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT xuzhou prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT liangxinyu prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT chenyuling prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT xiaojun prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT weijiaying prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT machenyu prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT songjingyu prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT sheruiling prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT wukainan prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors AT konglingquan prevalenceofhepaticsteatosisandmetabolicassociatedfattyliverdiseaseamongfemalebreastcancersurvivors |